Neo Performance Materials Inc
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.1K
- Market Cap
- -
- Introduction
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
NeoGenomics Launches c-MET Companion Diagnostic for Advanced Non-Small Cell Lung Cancer Treatment
NeoGenomics has commercially launched c-MET CDx for NSCLC, a companion diagnostic assay that detects c-Met protein overexpression in advanced non-small cell lung cancer patients with a 48-hour turnaround time.
NeoGenomics Expands Northeast Presence with Strategic Acquisition of Pathline
NeoGenomics has completed its acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey, strengthening its commercial footprint in the historically underpenetrated Northeast market.
Moderna-Merck's Personalized Cancer Vaccine Shows Strong Promise in Advanced Melanoma Trial
Moderna and Merck's personalized cancer vaccine mRNA-4157, combined with Keytruda, demonstrated a 65% reduction in risk of distant metastasis or death in high-risk melanoma patients.
Brain-Computer Interface Advances Enable Speech Synthesis and Action Control in Epilepsy Patient
A 43-year-old epilepsy patient with a brain tumor can now communicate and control actions through computer decoding of her thoughts, marking a significant BCI advancement.
Adaptive Biotechnologies Reports Strong MRD Business Growth in 2024 Financial Results
Adaptive Biotechnologies reported 42% growth in its Minimal Residual Disease (MRD) business for 2024, with clonoSEQ test volume increasing 35% to 76,105 tests delivered throughout the year.
China's NEO Brain-Computer Interface Set for Large-Scale Clinical Trials
China's NEO brain-computer interface (BCI) device is set to begin large-scale clinical trials next year, enrolling 30-50 spinal cord injury patients across 10 centers.